Kiniksa Pharmaceuticals (KNSA) Stock Forecast, Price & News

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kiniksa Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" KNSA shares.
View KNSA analyst ratings or view top-rated stocks.

1 Wall Street research analysts have issued twelve-month target prices for Kiniksa Pharmaceuticals' stock. Their KNSA share price forecasts range from $20.00 to $20.00. On average, they expect the company's stock price to reach $20.00 in the next twelve months. This suggests a possible upside of 22.5% from the stock's current price.
View analysts price targets for KNSA or view top-rated stocks among Wall Street analysts.

Kiniksa Pharmaceuticals' stock was trading at $14.98 at the start of the year. Since then, KNSA stock has increased by 9.0% and is now trading at $16.33.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 7th 2023.
View our KNSA earnings forecast.

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) announced its earnings results on Tuesday, July, 25th. The company reported ($0.02) earnings per share for the quarter, beating analysts' consensus estimates of ($0.16) by $0.14. The business had revenue of $71.47 million for the quarter, compared to analysts' expectations of $52.33 million. Kiniksa Pharmaceuticals had a net margin of 82.35% and a trailing twelve-month return on equity of 9.53%.

ETFs with the largest weight of Kiniksa Pharmaceuticals (NASDAQ:KNSA) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP).ALPS Medical Breakthroughs ETF (SBIO).

1 employees have rated Kiniksa Pharmaceuticals Chief Executive Officer Sanj K. Patel on Glassdoor.com. Sanj K. Patel has an approval rating of 100% among the company's employees. This puts Sanj K. Patel in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Kiniksa Pharmaceuticals investors own include Exelixis (EXEL), CRISPR Therapeutics (CRSP), Pfizer (PFE), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Dicerna Pharmaceuticals (DRNA), Vaxart (VXRT) and Advanced Micro Devices (AMD).

(KNSA) raised $126 million in an initial public offering (IPO) on Thursday, May 24th 2018. The company issued 7,000,000 shares at $17.00-$19.00 per share. Goldman Sachs and J.P. Morgan acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Kiniksa Pharmaceuticals trades on the NASDAQ under the ticker symbol "KNSA."

Kiniksa Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Rubric Capital Management LP (4.83%), BlackRock Inc. (4.52%), State Street Corp (2.35%), ArrowMark Colorado Holdings LLC (1.40%), Hudson Bay Capital Management LP (0.97%) and Rice Hall James & Associates LLC (0.94%). Insiders that own company stock include Barry D Quart, John F Paolini, Sanj K Patel and Thomas W Beetham.
View institutional ownership trends.

Shares of KNSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of KNSA stock can currently be purchased for approximately $16.33.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) has a market capitalization of $1.15 billion and generates $280.84 million in revenue each year. The company earns $183.36 million in net income (profit) each year or $3.27 on an earnings per share basis.

The company employs 220 workers across the globe.

Kiniksa Pharmaceuticals' mailing address is CLARENDON HOUSE 2 CHURCH STREET, HAMILTON D0, HM11. The official website for the company is www.kiniksa.com. The company can be reached via phone at (781) 431-9100 or via email at ir@kiniksa.com.